PolyPid

NAQ:PYPD · IL0011326795

PharmaceuticalsX-Small

360° View

Value48

Price/Sales1

Price/Earnings80

Price/Book95

Dividend Yield1

Growth23

Revenue Growth—

Profit Growth16

Capital Growth20

TSR 52w77

Safety24

Leverage67

Liquidity9

Refinancing23

Combined11

Sentiment56

Analyst Opinions61

Pro Holdings28

Opinion Changes50

Market Pulse75

Profile

CountryIsrael

IndustryPharmaceuticals

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Founded2008

Employees66

Websitepolypid.com

ISINIL0011326795

Last UpdateApr 2, 2026

Index & Theme

Pain ManagementInfectious DiseasesImmunologyOncologyOrthopaedicsSurgeryBiopharmaBiotechnologyPharmaceutical

Description

PolyPid Ltd. operates as a biopharmaceutical company. The company is dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins. The company develops long-acting, controlled-release medicines that deliver th…

Analysis

PolyPid's 360° View rank of 26 places it below its peer average — better than 26% of its true peers.

It's lagging on growth (23) and on the expensive side (48). On safety it is highly leveraged (24), and the market shows favorable sentiment (56). Taken together, its Combined rank of 11 reads as among the weakest overall.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare PolyPid with its peers

Pharming

AEX:PHARM

CountryNetherlands

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

OKYO Pharma

NAQ:OKYO

CountryUK

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

GH Research

NMQ:GHRS

CountryIreland

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

NewAmsterdam Pharma Company

NMQ:NAMS

CountryNetherlands

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Pentixapharm

GER:PTP

CountryGermany

IndustryHealth Care Equipment & Supplies

SizeX-Small

Full Stock Analysis →

Mediwound

NMQ:MDWD

CountryIsrael

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →